Virchow's triad revisited: The importance of soluble coagulation factors, the endothelium, and platelets [2]

Thrombosis Research

Volumn 101, Issue 4, 2001, Pages 321-327

  Blann, Andrew D ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE; PLASMIN; PLASMINOGEN; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOMODULIN; VON WILLEBRAND FACTOR; WARFARIN;

ATHEROSCLEROSIS; BLOOD RHEOLOGY; ENDOTHELIUM; HEART ATRIUM FIBRILLATION; HEMOSTASIS; LETTER; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE; THROMBOSIS; VISCOSITY;

ARTERIOSCLEROSIS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HEMORHEOLOGY; HUMANS; RISK FACTORS; SOLUBILITY; THROMBOSIS;

EID: 0035864727     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00419-9     Document Type: Letter

References (52)

1. Endothelial cells in physiology and in the pathophysiology of vascular disorders
2. The endothelium in atherothrombotic disease: Assessment of function, mechanisms and clinical implications
3. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
4. Increased levels of von Willebrand factor are related to a poor prognosis in systemic sclerosis and are unrelated to tissue autoantibodies
5. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis
6. von Willebrand factor antigen and fibronectin in essential hypertension
7. Changes in the factor VIII complex in diabetic ketoacidosis: Evidence of endothelial cell damage?
8. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease
9. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker
10. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells
11. Levels of plasma thrombomodulin are increased in atheromatous arterial disease
12. Serum thrombomodulin: A novel marker of disease activity in systemic lupus erythematosus
13. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease
14. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenia purpura patients with severe vascular endothelial cell injuries
15. Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long term anticoagulant treatment
16. The role of vascular endothelium in the pathogenesis of connective tissue disease: Endothelial injury, activation, participation and response
17. Plasma levels of beta thromboglobulin and platelet factor 4 as indices of platelet activation in vivo
18. Hypothesis: Is soluble P-selectin a new marker of platelet activation?
19. The origin of P-selectin as a circulating plasma protein
20. Beta thromboglobulin in acute myocardial infarction
21. Beta thromboglobulin, platelet production time and platelet function in vascular disease
22. Evaluation of beta thromboglobulin levels in cancer patients: Effects of antitumour chemotherapy
23. Plasma levels of beta thromboglobulin and factor VIII related antigen in diabetic children and adults
24. Platelet aggregation, coronary artery disease progression and future coronary events
25. Postangioplasty restenosis: Platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis
26. New approaches to antiplatelet therapy
27. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation
28. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry
29. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: Implications for atherogenesis? A preliminary report
30. Soluble form of P-selectin in patients with acute myocardial infarction
31. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor
32. Plasma P-selectin is increased in thrombotic consumptive disorders
33. Measurement of beta thromboglobulin and platelet factor 4 to follow up patients with artificial heart valves
34. Fibrinogen and cardiovascular disease
35. Prospective study of hemostatic factors and incidence of coronary heart disease. The atherosclerosis risk in communities (ARIC) study
36. Fibrin D-dimer: A useful clinical marker of thrombogenesis?
37. Increased fibrin turnover in peripheral artery disease: A comparison with a population study
38. Markers of a hypercoagulable state following acute ischaemic stroke
39. Fibrin D-dimer, haemostatic factors and peripheral arterial disease
40. Plasma concentration of cross linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
41. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study
42. Blood rheology, haemostasis and vascular disease
43. Von Willebrand factor, fibrinogen, and other plasma proteins as determinants of plasma viscosity
44. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants
45. Impaired fibrinolysis and the risk for coronary heart disease
46. Significance of raised plasma concentrations of tissue type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease
47. Fibrinolytic and inflammatory markers for arterial occlusion: The evolving epidemiology of thrombosis and haemostasis
48. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
49. Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction
50. Joint British recommendations on prevention of coronary heart disease in clinical practice
51. Soluble P-selectin and the Risk of Future Cardiovascular Events